Company intelligence / Profile preview

Bionor Holding

Ownership: Private
Employees: ~24
Development stage: Other

Overview

Bionor has developed proprietary therapeutic vaccines for HIV—Vacc-4x and Vacc-C5—with clinical trials completed for Vacc-4x monotherapy and combination strategies. The REDUC trial demonstrated safety and immunogenicity of their "shock & kill" approach. Additional candidates include CRX for HIV and preclinical programs for HCV and influenza. The company claims first-mover advantage based on its clinical results to date.

Therapeutic areas: Infectious Diseases
Modalities: Peptide vaccineSynthetic peptide
Industry: Biotech

Drug pipeline

4 assets

Vacc-4x

3 more assets in the full pipeline.

Partnerships

Smerud Medical Research International

Beyond the preview

Go deeper on Bionor Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bionor Holding.